---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-107780"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:38:42.994909+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Coherus Q3 LOQTORZI rev up 92% YoY to $11.2M; net loss narrows to $44.5M; CHS-114 enters colorectal cancer

## Summary
- Net revenue $11.6M (up 90% YoY); LOQTORZI net revenue $11.2M (+12% QoQ, +92% YoY).
- GAAP net loss from continuing ops $44.5M (-$0.38/sh) vs $47.6M (-$0.41/sh) prior year.
- Non-GAAP net loss $38.9M (-$0.33/sh) vs $40.0M (-$0.35/sh); cash at $191.7M.
- CHS-114 Phase 1b/2a enrolling in 4L+ colorectal cancer; initial data expected 2H 2026.
- Casdozokitug Phase 2 in 1L HCC enrollment ongoing; first data readout mid-2026.

## SEC filing metadata
- accession: 0001104659-25-107780
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000110465925107780/0001104659-25-107780-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000110465925107780/chrs-20251106x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-107780
- JSON: https://secwatch.observer/filing/0001104659-25-107780.json
- Plain text: https://secwatch.observer/filing/0001104659-25-107780.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.